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large population-based cohort of Hispanic/Latino subjects.
METHODS: Cross-sectional data on adults from the Hispanic Community Health Study/Study
of Latinos (2008-2011) were analyzed. Subjective and objective sleep measurements were
obtained. Clinically significant SA was defined as an apnea-hypopnea index $ 15 events per
hour. Using logistic regression, four prediction models were created: three sex-specific
models (female-only, male-only, and a sex  covariate interaction model to allow differen-
tial predictor effects), and one overall model with sex included as a main effect only. Models
underwent 10-fold cross-validation and were assessed by using the C statistic. SA and its
predictive variables; a total of 17 variables were considered.
RESULTS: A total of 12,158 participants had complete sleep data available; 7,363 (61%) were
women. The population-weighted prevalence of SA (apnea-hypopnea index $ 15 events per
hour) was 6.1% in female subjects and 13.5% in male subjects. Male-only (C statistic, 0.808)
and female-only (C statistic, 0.836) prediction models had the same predictor variables
(ie, age, BMI, self-reported snoring). The sex-interaction model (C statistic, 0.836) contained
sex, age, age  sex, BMI, BMI  sex, and self-reported snoring. The final overall model (C
statistic, 0.832) contained age, BMI, snoring, and sex. We developed two websites for our
SA risk calculator: one in English (https://www.montefiore.org/sleepapneariskcalc.html) and
another in Spanish (http://www.montefiore.org/sleepapneariskcalc-es.html).
CONCLUSIONS: We created an internally validated, highly discriminating, well-calibrated, and
parsimonious prediction model for SA. Contrary to the study hypothesis, the variables did
not have different predictive magnitudes in male and female subjects.
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Sleep apnea (SA) affects at least 25 million adults in the
United States.1,2 Historically, SA has been considered a
predominately male condition. Clinic-based studies
have estimated that the prevalence of SA among men
compared with women approaches a ratio of 8:1.3,4 As
a result, SA-screening tools have been based on male-
specific SA symptoms such as snoring and excessive
daytime sleepiness. Women, however, tend to
underreport these “classic” symptoms of SA.3 Instead,
women with SA frequently present with symptoms such
as lack of energy, depression, and insomnia,5,6 and these
female-specific SA symptoms are not routinely captured
in current SA prediction tools. Therefore, a need for
sex-specific SA screening tools is obvious. Furthermore,
sex-specific SA prediction tools are now even more
necessary, with epidemiologic evidence revealing a
higher than previously reported prevalence of SA in
women. The ratio of SA in men compared with
women is currently believed to be closer to 2 to 3:1
(vs 8:1).3,7,8
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1410 Original Researchundiagnosed.9 This scenario is partly due to the
concerns highlighted earlier, which include sex-related
differences in the clinical presentation of SA and lack
of sex-specific prediction tools for SA. Interestingly,
well-established prediction tools for other diseases
(eg, coronary heart disease) have demonstrated the
importance of incorporating sex-specific variables to
improve the predictive ability.10,11 The same may be
true for SA, but further investigation is needed.
To create a comprehensive prediction tool for SA that
captures sex-specific symptoms, we designed a study in
the Hispanic Community Health Study/Study of Latinos
(HCHS/SOL), the largest known population-based
study to date with objective SA data. In the present
study, we developed and validated sex-specific
prediction equations for SA by using symptom,
demographic, and anthropometric data. We assessed
whether incorporating sex differences improves SA
prediction by using established measures of model
discrimination. The study hypothesis was that sex-
specific prediction models would perform better than
a non-sex-specific prediction model for SA.Materials and Methods
The Albert Einstein College of Medicine institutional review board
approved the HCHS/SOL protocol prior to data collection. Their
institutional review board number is 2007-432, and their reference
number is 008048.
Study Population
HCHS/SOL is a community-based cohort study sponsored by the
National Institutes of Health consisting of 16,415 self-identified
Hispanic/Latino participants aged 18 to 74 years residing in four US
sites (Bronx, New York; Chicago, Illinois; Miami, Florida; and San
Diego, California). The details of the study design, sampling strategy,and recruitment have been described elsewhere.12,13 All participants
underwent a baseline interview and an extensive clinic examination
(2008-2011) that included but was not limited to anthropometry,
ECG, blood pressures in both arms, phlebotomy, glucose tolerance
testing, audiometry, lung function, and oral examination.
Questionnaires included sociodemographic characteristics, health and
medical history, smoking, alcohol, medication use, occupational
history, diet, and physical activity.
Assessment of Sleep-Disordered Breathing
In HCHS/SOL, both subjective and objective sleep data were
collected. The sleep questionnaire included SA symptoms,
questions, and sleep patterns from the sleep habits questionnaire of
the Sleep Heart Health Study14 and the Epworth Sleepiness Scale
(ESS).15 Objective SA testing included a home sleep test using the
ARES Unicorder 5.2 (B-Alert).16 The ARES monitor is a self-
applied device that measures blood oxygen saturation and pulse
rate (reflectance pulse oximetry), airflow (by nasal cannula
connected to a pressure transducer), snoring levels (calibrated
acoustic microphone), and head movement and head position
(accelerometers). The sleep data were scored by the HCHS/SOL
Sleep Reading Center. Respiratory events were defined as a
$ 50% reduction in airflow lasting at least 10 s. Apneas were not
distinguished from hypopneas because thermistry testing was not
available. Each respiratory event was manually identified and linked
to its level of desaturation, and artifacts were manually edited on
an epoch-by-epoch basis. The present analyses used the
3% desaturation variable in accordance with current recommended
scoring criteria from the American Academy of Sleep Medicine.17,18
The majority of the sleep studies ($ 80%) included in the analyses
had $ 4 h of total recording time. Sleep studies with < 30 min
were defined as incomplete and were excluded. The apnea-
hypopnea index (AHI) data obtained from the ARES has an
excellent correlation with AHI data obtained from in-laboratory[ 1 4 9 # 6 CHES T J U N E 2 0 1 6 ]
polysomnography.16,19 The primary definition of SA was established
by using an AHI of $ 15 events per hour. An AHI $ 15 events per
hour was chosen as our cut point to define SA and thus enable the
capture of moderate and severe SA, which are typically associated
with adverse cardiovascular outcomes rather than milder degrees of
SA.20,21 Mild SA was defined as an AHI $ 5 events per hour
and < 15 events per hour; moderate SA as AHI $ 15 events per
hour and < 30 events per hour; and severe SA as AHI $ 30 events
per hour. Interscorer and intrascorer reliability estimates for the
AHI, assessed over the course of the study, were excellent
(intraclass correlation coefficients, > 0. 99).
Variables Considered for Prediction Models
Waist and hip circumference were measured to compute the waist-
to-hip ratio. Insomnia, hypertension, diabetes, and heart disease
were self-reported (yes/no). Depressive symptoms were assessed by
using the Center for Epidemiologic Studies Depression (CESD)
scale (10-item version).22 A CESD score (range, 0-30) $ 10 was
considered indicative of depression symptoms. The question “Have
you felt downhearted and depressed?” was also used to assess
symptoms of depression. Energy level of participants was assessed by17 covariates considered
and
covariate × sex interactions
0.845 0.844 0.836 0.
Female-only model
n = 7,363 
M
1a 2b Final
1. Sex
2. Age
Age × sex
3. BMI
BMI × sex
4. Waist circumference
Waist circumference × sex
5. Hypertension
Hypertension × sex
6. Diabetes
7. Heart disease
Heart disease × sex
8. Average sleep duration
9. Trouble falling asleep
Trouble falling asleep × sex
10. ESS > 10 
11. Snoring
12. Witnessed apneas 
13. Naps
14. Awakenings at night
Awakenings at night × sex
15. Energy level next day
16. Feeling down
Feeling down × sex 
17. Restless sleep
Restless sleep × sex
Area under the curve
Figure 1 – The model selection process for the three sex-specific models and the
predictor variables were considered. The secondary phase (2b) refined models b
and the Hosmer-Lemeshow test to evaluate calibration, ending with a “Final
male-only model; gray indicates sex  covariate interaction model; orange ind
Epworth Sleepiness Scale.
journal.publications.chestnet.orgusing the question, “Did you have a lot of energy?” Reponses to
these questions were collapsed into yes/no (yes ¼ all or most of the
time; no ¼ some, a little, or none of the time). Snoring, witnessed
apneas, naps, difficulty falling asleep, excessive daytime sleepiness
(EDS), and nighttime awakenings were defined as present if
participants reported each occurring $ 3 times per week based on
standardized questions. An ESS score23 (range, 0-24) $ 10 was used
to define EDS. Restless sleep was present if participants reported
“restless” or “very restless” sleep in the past 4 weeks. Finally, average
self-reported sleep duration was obtained.
Of these variables, 17 candidate predictors were considered in risk
prediction models after significance testing in bivariate comparisons.
Figure 1 summarizes the model selection process for the three sex-
specific models (female-only, n ¼ 7,363; male-only, n ¼ 4,795; sex 
covariate interaction model, n ¼ 12,158) as well as the non-sex-
specific model (n ¼ 12,158).Statistical Analysis
Baseline demographic characteristics, comorbidities, and sleep
characteristics were compared according to SA status and sex. Chi-818 0.817 0.808 0.844 0.843 0.836 0.832
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square and Wilcoxon tests were used for significance testing as
appropriate. To test our hypothesis (ie, sex-specific prediction
models [including models that include sex interaction terms] would
outperform a non-sex-specific model for predicting SA), we created
and compared the three aforementioned models with a non-sex-
specific model.
All continuous variables were examined graphically for linearity, with
transformations and piecewise functions considered. Logistic
regression was used with backward elimination to identify significant
predictors (P < .20 to consider, P < .05 to stay) for each model.
As noted earlier, sex  covariate interaction terms were considered
for variables that differed significantly with respect to SA status
according to sex: age, BMI, waist circumference, hypertension, heart
disease, trouble falling asleep, waking up several times at night,
feeling downhearted, and restless sleep. We then systematically left
out predictors and evaluated changes in the C statistic to determine
each covariate’s contribution to model discrimination. The more
parsimonious models were selected to develop a clinically useful
prediction tool, and calibration was considered (based on the
Hosmer-Lemeshow test), prioritizing models with better goodness-
of-fit. After the final sets of predictors were selected, 10-fold1412 Original Researchcross-validation was used to internally validate prediction models.24
Cross-validation is a model validation procedure to assess the
generalizability of a prediction model to an independent dataset. The
10-fold cross-validation method divides the dataset into 10 sets of
size n/10, using 9 datasets as “training” datasets and 1 as the “test”
dataset; this process was repeated 10 times. Performance statistics
were determined within each iteration, and these values were then
combined across the 10 sets.
Discrimination was assessed by using the following performance
measures: receiver-operating characteristic curves, category-free net
reclassification improvement, and integrated discrimination
improvement.25 The specificity and sensitivity of each model were
also determined, using the probability cutoff maximizing the sum of
these two measures to define SA (AHI $ 15 events per hour).
Analyses were performed by using SAS version 9.3 (SAS Institute,
Inc) and SUDAAN software Release 11 (RTI International).
Cross-validation and performance measures were conducted by
using R 2.15.2 (R Foundation for Statistical Computing) with
the R package ROCR26 and in SAS with the %add_predictive
macro.27Results
A total of 16,415 participants completed the baseline
examination from 2008 to 2011. Of these, 15,277
participants had undergone home sleep testing; 12,531
of these subjects had acceptable sleep study quality
(ie, > 30 min of recording). Complete data on all
variables were available on 12,158 participants
(373 had missing data).
The population-weighted prevalence of SA (AHI $ 15
events per hour) was 6.1% (95% CI, 5.3-7.0) in female
subjects and 13.5% (95% CI, 12.4-14.8) in male
subjects. Table 1 provides baseline demographic
characteristics and comorbidities for HCHS/SOL
participants with SA, grouped according to sex.
Women with SA (AHI $ 15 events per hour) were
older and had a higher BMI compared with men with
SA. Among both male and female subjects, age, BMI,
and waist circumference were significantly higher in
the SA-positive group compared with the SA-negative
group. Similarly, in both men and women, the
prevalence of self-reported hypertension, diabetes, and
heart disease was significantly higher in SA-positive
participants compared with SA-negative participants
(data for SA-negative subjects not shown in Table 1).
Compared with SA-positive male subjects, SA-positive
female subjects had a higher prevalence of symptoms
of insomnia (nocturnal awakenings, 51% in women
vs 35% in men [Pinteraction ¼ .03]; trouble falling asleep,
33% vs 13% [Pinteraction < .0001]; and restless sleep,
25% vs 14% [Pinteraction ¼ .06]) and depressed mood
(feeling downhearted or depressed, 18% in femalesubjects vs 8% in male subjects [Pinteraction ¼ .03]).
Interestingly, the presence of snoring, EDS (ESS $ 10),
and depression symptoms (CESD $ 10) among men
and women with SA was not significantly different
(68% and 67%, Pinteraction ¼ .40; 23.5% vs 24.4%,
Pinteraction ¼ .88; and 20.6% vs 36.7%, Pinteraction ¼ .19,
respectively).
Table 2 provides the results for predicting SA from the
logistic regression analyses for each model. Female-only
and male-only prediction models both consisted of age,
BMI, and self-reported snoring. Older age was
associated with SA more in women compared with men
(OR, 1.09 per year vs 1.06 per year; Pinteraction < .0001),
and higher BMI was associated with SA more in men
compared with women (OR, 1.19 per kg/m2 vs 1.13
per kg/m2; Pinteraction < .0001).
Table 3 provides comparisons of performance indicators
among the four prediction models after 10-fold
cross-validation. Comparing C statistics (Fig 2), the
female-only model (C statistic, 0.836) outperformed
both the male-only model (0.808) and the non-sex-
specific model (C statistic, 0.832) but performed
similarly to the sex  covariate interaction model
(C statistic, 0.836). The sex  covariate interaction
model performed statistically better than the non-sex-
specific model based on sensitivity at the probability
cutoff that maximized these measures, area under the
curve (C statistic, 0.836 vs 0.832; P < .0001), category-
free net reclassification improvement (24.3% [95% CI,
18.7-29.9]; P < .0001), and integrated discrimination
improvement (0.8% [95% CI, 0.5-1.0]; P < .0001).[ 1 4 9 # 6 CHES T J U N E 2 0 1 6 ]
TABLE 1 ] Baseline Demographic/Sleep Characteristics and Comorbidities for HCHS/SOL Participants With SA,
Grouped According to Sex
Variable
Male Subjects (n ¼ 4,795) Female Subjects (n ¼ 7,363)
SA-Positive
(n ¼ 807)
SA-Negative
(n ¼ 3,988) P Value
SA-Positive
(n ¼ 561)
SA-Negative
(n ¼ 6,802) P Value
Age, y 53 (46-61) 46 (33-55) < .001 57 (52-64) 48 (37-56) < .001
BMI, kg/m2 32 (29-35) 28 (25-31) < .001 34 (30-39) 29 (26-33) < .001
Waist circumference, cm 106 (99-115) 96 (89-104) < .001 107 (99-116) 96 (88-104) < .001
ESS (range, 0-24) 6 (3-9) 5 (2-9) < .001 6 (3-9) 5 (2-8) < .001
ESS score $ 10
Yes 190 (24) 728 (18) < .001 137 (24) 1,269 (19) < .001
No 617 (77) 3,260 (82) 424 (76) 5,533 (81)
CESD-10 score $ 10
Yes 166 (21) 840 (21) .75 206 (37) 2,278 (34) .12
No 641 (79) 3,148 (79) 355 (63) 4,524 (67)
Hypertensiona
Yes 378 (47) 949 (24) < .001 311 (55) 1,846 (27) < .001
No 429 (53) 3,039 (76) 250 (45) 4,956 (73)
Diabetesa
Yes 181 (22) 440 (11) < .001 171 (31) 1,047 (15) < .001
No 626 (78) 3,548 (89) 390 (70) 5,755 (85)
History of heart disease
(excludes angina)a
Yes 64 (8) 139 (4) < .001 42 (8) 136 (2) < .001
No 743 (92) 3,849 (97) 519 (93) 6,666 (98)
Snoringa
$ 3 times a week 551 (68) 1,555 (39) < .001 374 (67) 2,386 (35) < .001
< 3 times a week 125 (16) 1,333 (33) 72 (13) 2,307 (34)
Do not know 131 (16) 1,100 (28) 115 (21) 2,109 (31)
Witnessed apneasa
$ 3 times a week 163 (20) 282 (7) < .001 82 (15) 411 (6) < .001
< 3 times a week 290 (36) 2,082 (52) 179 (32) 3,243 (48)
Do not know 354 (44) 1,624 (41) 300 (54) 3,148 (46)
Naps ($ 5 min) per weeka
$ 3 times a week 257 (32) 1,068 (27) .003 153 (27) 1,365 (20) < .001
< 3 times a week 550 (68) 2,920 (73) 408 (73) 5,437 (80)
Wake up several times at nighta
$ 3 times a week 280 (35) 1,132 (28) < .001 284 (51) 2,487 (37) < .001
< 3 times a week 527 (65) 2,856 (72) 277 (49) 4,315 (63)
Restless sleep in past 4 weeksa
Restless or very restless 116 (14) 591 (15) .74 140 (25) 1,404 (21) .02
Very sound, sound, or
average
691 (86) 3,397 (85) 421 (75) 5,398 (79)
Did you have a lot of energy?a
Some, a little, or none of the
time
252 (31) 1,008 (25) < .001 298 (53) 3,033 (45) < .001
All or most of the time 555 (69) 2,980 (75) 263 (47) 3,769 (55)
(Continued)
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TABLE 1 ] (Continued)
Variable
Male Subjects (n ¼ 4,795) Female Subjects (n ¼ 7,363)
SA-Positive
(n ¼ 807)
SA-Negative
(n ¼ 3,988) P Value
SA-Positive
(n ¼ 561)
SA-Negative
(n ¼ 6,802) P Value
Have you felt downhearted and
depressed?a
All or most of the time 61 (8) 302 (8) .99 103 (18) 881 (13) < .001
Some, a little, or none of the
time
746 (92) 3,686 (92) 458 (82) 5,921 (87)
Trouble falling asleepa
$ 3 times a week 106 (13) 703 (18) .002 186 (33) 1,811 (27) < .001
< 3 times a week 701 (87) 3,285 (82) 375 (67) 4,991 (73)
Data are presented as median (interquartile range) or no. (%). CESD ¼ Center for Epidemiologic Studies Depression Scale; ESS ¼ Epworth Sleepiness Scale;
SA ¼ with sleep apnea.
aSelf-reported variables.However, because the C statistics were nearly identical
in the sex  covariate interaction model and the
non-sex-specific model, and because the non-sex-
specific model is simpler, we report the non-sex-specific
model as our final model, with the prediction equation
as follows:
Predicted probability of SA ¼ 1=½1 þ exp
½½10:2561 þ 0:7006 ð1 if male; 0 if femaleÞ
þ 0:0655 ðageÞ þ 0:1391 ðBMIÞ þ 0:9481
 ð1 if snores  3 times a week; 0 if otherwiseÞ
þ 0:1012 ð1 if does not know snoring status;
0 if otherwiseÞ 
Following is an example of how our prediction model
can be applied:
Predicted probability of SA for a 50-year-old man
with of 32 kg=m2 who does not know if he snores
¼ 1=½1þ exp ½½10:2561þ 0:7006 1þ 0:0655
 50þ 0:1391 32þ 0:9481 0þ 0:1012 1 ¼ 0:151
Therefore, the predicted probability of SA in this patient
is 15.1% (95% CI, 13.2-17.1), with a sensitivity of 0.77 and
a specificity of 0.75 using a probability cutoff of $12%.Discussion
We developed and internally validated a simple yet
highly discriminating, well-calibrated, and parsimonious
prediction model for SA. Using this model, we created
English (https://www.montefiore.org/sleepapneariskcalc.
html) and Spanish (http://www.montefiore.org/
sleepapneariskcalc-es.html) websites in which we display1414 Original Researchour SA risk calculator. The SA prediction model was
created from a community-based sample of US
Hispanic/Latino subjects, the largest population-based
cohort study to date with subjective and objective SA
measurements. Our model consisted of four commonly
available variables: self-reported snoring, age, sex, and
BMI. The model had a sensitivity of 0.77 and a
specificity of 0.75. Contrary to our hypothesis, the same
set of variables predicted SA in both sexes in our study
sample. The risk prediction model we developed may
be a more useful tool for predicting SA in the general
population compared with previously published models
due to its ease of use (ie, four easily measured variables)
and high discrimination.
SA is common in the United States and, despite its
high prevalence, it remains vastly underdiagnosed.28
Furthermore, the majority of published data on SA
screening and diagnosis originates from non-Hispanic/
Latino study samples, which limits their generalizability.
The prevalence of SA and its associated risk factors is
common among US Hispanic/Latino subjects.8
Development of prediction tools for SA in the US
Hispanic/Latino population is therefore crucial for
identifying high-risk individuals. In addition to the lack
of representation of the Hispanic/Latino population
in currently available prediction tool source cohorts,
these other tools have several limitations: (1) most
prediction tools for SA were developed in referral-based
samples of symptomatic individuals, (2) most prediction
tools require complex measurements (eg, neck, hip
circumference) or completion of laborious
questionnaires, and (3) sex-related SA symptoms are
often not considered in these prediction tools.[ 1 4 9 # 6 CHES T J U N E 2 0 1 6 ]
TABLE 2 ] Results From Logistic Regression Analysis for Each Model Predicting Sleep Apnea
Variable Beta Coefficient Lower Limit of 95% CI Upper Limit of 95% CI P Value
Sex  covariate interaction model, n ¼ 12,158
Intercept –11.24 –12.04 –10.43 < .0001
Male (vs female) 1.04 –0.06 2.14 .07
Age (per year) 0.08 0.07 0.09 < .0001
Age  male –0.03 –0.04 –0.02 < .0001
BMI (per kg/m2) 0.12 0.10 0.13 < .0001
BMI  male 0.06 0.04 0.08 < .0001
Snoring (vs < 3 nights a week)
$ 3 times a week 0.92 0.75 1.10 < .0001
Do not know 0.08 –0.13 0.29 .46
Male-only model, n ¼ 4,795
Intercept –10.18 –10.95 –9.42 < .0001
Age (per year) 0.06 0.05 0.06 < .0001
BMI (per kg/m2) 0.18 0.16 0.19 < .0001
Snoring (vs < 3 nights a week)
$ 3 times a week 0.89 0.67 1.11 < .0001
Do not know 0.06 –0.22 0.33 .67
Female-only model, n ¼ 7,363
Intercept –11.26 –12.08 –10.45 < .0001
Age (per year) 0.08 0.07 0.09 < .0001
BMI (per kg/m2) 0.12 0.10 0.13 < .0001
Snoring (vs < 3 nights a week)
$ 3 times a week 0.97 0.70 1.24 < .0001
Do not know 0.11 –0.20 0.43 .49
Non-sex-specific model, n ¼ 12,158
Intercept –10.26 –10.79 –9.72 < .0001
Male sex (vs female) 0.70 0.63 0.77 < .0001
Age (per year) 0.07 0.06 0.07 < .0001
BMI (per kg/m2) 0.14 0.13 0.15 < .0001
Snoring (vs < 3 nights a week)
$ 3 times a week 0.95 0.78 1.12 < .0001
Do not know 0.10 –0.11 0.31 .34Unlike existing prediction models, our models
systematically examined the impact of sex-related
differences in SA prediction. A population-based study29
conducted in 1990 examined the prevalence of SA
symptoms, in particular snoring, in a Hispanic/Latino-
American population. In this study of 1,222 individuals,
regular loud snoring was more common in male subjects
(27.8%) than in female subjects (15.3%). However, in
our sample of community-dwelling US Hispanic/Latino
subjects, we found no difference in self-reported snoring
between the two sexes. We also found that the same
set of variables predict SA in both sexes. This outcomejournal.publications.chestnet.orgwas contrary to our hypothesis. Despite finding
differences in the prevalence of insomnia and depression
symptoms among men and women with SA, these
symptoms did not result in improved SA prediction in
either sex. This finding may be partly due to their
expected high correlation with other predictor variables
such as age and BMI. Another possible explanation is
the increasing prevalence of obesity over the past few
decades, which could be influencing sex-specific
differences in SA. Finally, evidence that SA symptoms
may differ according to sex originates from studies that
consisted predominantly of non-Hispanic/Latino1415
TABLE 3 ] Comparisons of Performance Measures Among the Four Prediction Models After 10-Fold
Cross-Validation
Model (Covariates Included)
Performance Measures
Training Set C
Statistic
Test Set C Statistic
(10-Fold Validation)
Probability at Which
Sensitivity and Specificity
Are Maximized, % Sensitivity Specificity
Female-only (age, BMI,
snoring)
0.84 0.84 $ 7.0 0.82 0.70
Male-only (age, BMI,
snoring)
0.81 0.81 $ 15.7 0.78 0.70
Sex  covariate interaction
model (age, age  sex,
BMI, BMI  sex, snoring )
0.84 0.84 $ 11.3 0.79 0.73
Non-sex-specific model
(age, BMI, snoring, sex)
0.83 0.83 $ 12.0 0.77 0.75
Female-only model
Male-only model
Sex × covariate interaction model
Non-sex-specific model
1 – specificity
0.0
0.0
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Figure 2 – Receiver-operating characteristic curves for sleep apnea
prediction models displaying the trade-off between sensitivity and
specificity for each model. Visual comparison of performance of the four
models: (1) female-only, (2) male-only, (3) sex  covariate interaction
model, and (4) non-sex-specific model.individuals. Therefore, our findings could be partially
explained by the possibility that sex-specific differences
in reporting of SA symptoms are cultural.
Several questionnaire-based prediction tools exist in the
current literature. For example, the Berlin Questionnaire
captures symptoms of snoring, wake-time sleepiness
or fatigue, and history of hypertension and obesity.30 It
was tested in 744 adults surveyed in five primary care
sites in Cleveland, Ohio. Of the 744 surveys, only
100 had objective sleep data (from portable home sleep
monitoring). Being in the high-risk group predicted
presence of mild SA with a sensitivity of 0.86 and a
specificity of 0.77. However, a high-risk score predicted
moderate and severe SA, with a sensitivity of 0.54 and a
specificity of 0.97. These findings suggest that the
Berlin Questionnaire is an excellent screening tool for
mild SA but is less sensitive for moderate to severe SA.
Our prediction model, conversely, has a much higher
sensitivity (0.77) for predicting moderate to severe SA
without compromising specificity (0.75). We considered
our model performance by using an AHI cutoff of
5 events per hour for mild SA and found that our
model performs equally well (C statistic of 0.817 vs 0.833
using an AHI cut point of $ 15 events per hour).
The ESS31 is another questionnaire-based prediction
tool commonly used in clinical practice to assess for
EDS. It has been examined for its ability to predict
underlying SA and has been found to correlate well
with the AHI.23 However, the ESS did not improve the
predictive ability of our models.
Limitations of the present study need to be considered.
First, SA symptoms were captured by using a
questionnaire and are therefore susceptible to1416 Original Researchinformation bias. Self-reported snoring may be difficult
to report because symptoms occur during sleep;
nonetheless, this symptom is commonly used in
clinical assessments and research. Second, the
HCHS/SOL assessed SA with an in-home sleep study
as opposed to in-laboratory, full-night, attended
polysomnography. This approach may modestly
underestimate SA severity and does not allow
assessment of sleep stages, duration, or fragmentation.
Furthermore, although we assessed the internal validity
of our prediction model, we have not assessed the
external validity of our prediction models. Although
there are clear merits to examining sleep in the
understudied US Hispanic/Latino population and,[ 1 4 9 # 6 CHES T J U N E 2 0 1 6 ]
accordingly, to developing prediction models for SA in
this population (as we have), the generalizability of our
prediction models to non-Hispanic/Latino subjects
remains unclear and needs further investigation. We
therefore plan to externally validate our prediction
models in other population-based cohort studies.
Finally, population-based prediction rules are useful in
that they can identify SA among those less likely to be
referred for sleep testing. However, such models may
perform differently among patients already referred to
specialty sleep clinics, at which the disease prevalence
can vary significantly, resulting in underestimation
or overestimation of the probability of disease. Thisjournal.publications.chestnet.orgscenario was illustrated by use of the Berlin
Questionnaire, which performs relatively poorly in
sleep clinic settings compared with primary care
settings.32Conclusions
We developed and internally validated a highly
discriminating, well-calibrated, and parsimonious
prediction model for SA in a community-based sample
of US Hispanic/Latino subject. This model consisted of
four commonly available variables (snoring, age, sex,
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